Health Care Professionals Log In

Tracking Breakthrough Bleeding

Breakthrough bleeding is likely when taking LYBREL® and occurs most often during the first 7 pill packs of LYBREL use. It tends to decrease with subsequent pill packs.1 That's why we've created the Progress Tracker for LYBREL. This printable resource is designed to help your patients:

  • Monitor any bleeding they experience while taking LYBREL
  • Indicate what type of bleeding they experience on a daily and monthly basis
  • Make note of any changes in bleeding

Download the Progress Tracker (Daily Worksheet and Monthly Summary). Requires Adobe® Reader®

Get Adobe® Reader®

Next: Patient Education Materials »

Important Safety Information

  • Oral contraceptives (OCs) do not protect against HIV infection or other sexually transmitted diseases.
  • When prescribing LYBREL, the convenience of having no scheduled menstrual bleeding should be weighed against the inconvenience of unscheduled breakthrough bleeding and spotting.
  • OCs are contraindicated in women who have blood clots; breast, uterine, or liver cancers; a history of heart attack, stroke, or breast cancer; as well as those who are or may be pregnant.
The risks of serious cardiovascular side effects are substantially increased in women who smoke and use OCs, especially in women over age 35. Women who use oral contraceptives should be strongly advised not to smoke.
  • Serious risks associated with OCs include blood clots, heart attack, and stroke.
  • LYBREL provides women with more hormonal exposure on a yearly basis (13 additional weeks of hormone intake per year) than conventional cyclic oral contraceptives containing the same strength of synthetic estrogens and similar strength of progestins.
  • Scheduled withdrawal bleeding does not occur with the use of LYBREL, therefore, the absence of withdrawal bleeding cannot be used as a sign of an unexpected pregnancy and as such, unexpected pregnancy may be difficult to recognize. Although pregnancy is unlikely if LYBREL is taken as directed, if for any reason, pregnancy is suspected in a woman using LYBREL, a pregnancy test should be performed.
  • The most commonly reported treatment emergent adverse events reported with LYBREL in a clinical trial were headache, dysmenorrhea, upper respiratory infection, vaginal bleeding (defined as metrorrhagia and vaginal hemorrhage), and nausea.

Registration | Unsubscribe | E-mail This Page | Patient Awareness | Patient Support Program | References

206810-01

LYBREL and LYBREL with icon are registered trademarks of Wyeth.